MedTrace Logo

DS1040b/Aspirin Drug/Drug Interaction Study

NCT02071004 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-12-24

No results posted yet for this study

Summary

This is a phase 1, open label, single dose study, after 5 days of aspirin treatment, in healthy male and female subjects. It is hypothesized that co-administering DS-1040b with aspirin at steady state will be safe and well tolerated by healthy male and female subjects.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

DS-1040b

IV of 6 mg given once over 30 minutes

DRUG

Aspirin

Dispersible tablet, 300mg \& 75 mg, once daily for 5 days

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02071004 on ClinicalTrials.gov